VistaGen FY27 Q1 net loss narrows to $13.03 million; revenue rises to $1.48 million
VTGN•Quarterly results improve year over year
VistaGen posted Q1 FY2027 revenue of USD 1.48 million, up from USD 244,000 a year earlier.
Net loss narrowed to USD 13.03 million from USD 15.1 million; loss per share improved to USD 0.3 from USD 0.47.
R&D costs edged down to USD 10.91 million from USD 11.68 million; G&A expense fell to USD 3.92 million from USD 4.37 million.
Cash position and fasedienol development plans
Cash, cash equivalents, and marketable securities totaled USD 31.7 million at June 30, 2026; runway expected into 2027.
FDA engagement is planned this quarter on a potential Phase 3 path for fasedienol after PALISADE-4 missed its primary endpoint overall.
